Testing the use of a single drug (olaparib) or the combination of two drugs (cediranib and olaparib) compared to the usual chemotherapy for women with platinum sensitive ovarian, fallopian tube, or primary peritoneal cancer

What we are studying

The purpose of this study is to compare the effect on cancer of using either olaparib by itself or the combination of cediranib and olaparib to the usual chemotherapy given for cancer (carboplatin and paclitaxel; carboplatin and gemcitabine; or carboplatin and pegylated liposomal doxorubicin [PLD]). Any of these different approaches could shrink cancer but could also cause side effects. This study will allow the researchers to learn whether giving olaparib by itself or giving the combination of cediranib and olaparib is better, the same, or worse than the usual chemotherapy by observing both the effect of these treatments on cancer as well as any side effects that may be experienced. Both olaparib and cediranib have already been tested for safety; however, they are not part of the standard approach. Olaparib by itself has been approved by the Food and Drug Administration (FDA) for women with advanced ovarian cancer and a mutation in either BRCA1 or BRCA2 (these are genes in which mutations can be inherited that have been linked to a higher risk of developing cancers, including breast and ovarian cancer) who have received three or more prior treatments for their cancer. The use of olaparib in the setting of platinum-sensitive recurrent ovarian cancer is still being studied and is not FDA-approved. The combination of olaparib and cediranib is still being studied and is not yet FDA-approved.

Who is Eligible

  • Genders:
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Have platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian primary peritoneal or fallopian tube cancers

What is involved

  • Study Medication


Parking will be validated for study-related visits.

Contact Information

Study Coordinator
Melissa Swain
Principal Investigator
Samuel Lentz, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.